<?xml version="1.0" encoding="UTF-8"?>
<p>The DPP-4 inhibitors developed for the treatment of diabetes type II as well as the Î±-thrombin and Factor Xa inhibitors, used as anti-coagulants, may not be appropriate for patients who do not suffer such problems. However, they may be worth consideration for patients already being treated for type II diabetes or with anti-coagulants. Moreover, higher platelet count and increased coagulation features are observed in COVID-19 patients with severe pneumonia compared to patients with non SARS-CoV-2-induced pneumonia. Furthermore, according to recent results, anti-coagulant treatment by heparin administration reduced mortality of COVID-19 patients with severe pneumonia and markedly elevated D-dimers [
 <xref rid="B35-molecules-25-02529" ref-type="bibr">35</xref>].
</p>
